Morgan Stanley Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung maintains an Equal-Weight rating on PTC Therapeutics and raises the price target from $32 to $45.
October 11, 2024 | 4:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has increased the price target for PTC Therapeutics from $32 to $45, maintaining an Equal-Weight rating. This suggests a positive outlook on the stock's potential performance.
The increase in price target from $32 to $45 by Morgan Stanley indicates a more optimistic view on PTC Therapeutics' future performance. Maintaining an Equal-Weight rating suggests that while the stock is expected to perform well, it may not outperform the market significantly. This news is likely to have a positive short-term impact on the stock price as it reflects increased confidence from a major financial institution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100